New Research Suggests Novel Insulin Sensitizer Works Through a New Mechanism to Treat Root Cause of Type 2 Diabetes

Washington University School of Medicine researchers show MSDC compound has anti-diabetic efficacy without side effects profile of current drugs to treat insulin resistance

A study published online in the Journal of Biological Chemistry, titled “Insulin Resistance and Metabolic Derangements in Obese Mice are Ameliorated by a Novel Peroxisome Proliferator-Activated Receptor-sparing Thiazolidinedione”, showed a new drug to treat diabetes being developed by Metabolic Solutions Development Company (MSDC), MSDC-0602, improved insulin resistance and inflammation in obese mice. These findings suggest that MSDC-0602, a novel anti-diabetic drug which is in Phase 2 clinical trials, may constitute the first in a class of next generation insulin sensitizers that appear to work through a new biochemical mechanism to treat insulin resistance and type 2 diabetes.

Read more...